lexisnexis whitepaper

Download whitepaper – Pharmaceutical & Life sciences: Third Party Due Diligence

Whitepaper by LexisNexis

Few industries are as exposed to risk as the pharmaceuticals and life sciences. It is no longer enough to carry out basic checks alone on third-parties. Companies must engage in enhanced due diligence if they are to avoid the large fines and regulatory penalties.

Effective third-party due diligence is increasingly recognized as a strategic driver for sustainable business growth when moving into new and developing markets. It is no longer enough to carry out basic checks alone on third-parties. Companies must engage in enhanced due diligence if they are to avoid the large fines and regulatory penalties.

To help organisations in the sector meet the challenge of enhanced third-party due diligence, LexisNexis has created an ebook ‘Something Missing?  Pharmaceutical & Life Sciences Third-Party Due Diligence’. The ebook can be downloaded at the link below.

 

Download Whitepaper

 

LexisNexis are sponsors at our upcoming Pharma Compliance Congress, join the event today for the lowest prices!

Leave a Reply

Your email address will not be published. Required fields are marked *